Many of us in primary care and obesity medicine have similar anecdotes on our patients and hope to one day have a peer reviewed study of the benefit of GLPs in our rheumatoid patients. -Dr
Bombesin reduces food intake in lean man by a cholecystokinin-independent mechanism
Dovato, which combines the integrase strand transfer inhibitor dolutegravir with the nucleoside reverse transcriptase inhibitor lamivudine, was approved to treat HIV-1 infection in adolescents 12 years and older, making it the first oral, two-drug, single-tablet regimen available for this patient population, according to ViiV
B.La StoriaA.LaghiL.et al
This result indicates that coagulation markers may serve as indicators for monitoring the severity and treatment progress of heat stress
Key results at 80 weeks: Participants on the 4 mg dose lost an average of 47.2 lbs (19.0%) Participants on the 12 mg dose lost an average of 70.3 lbs (28.3%) 45.3% of participants on the 12 mg dose achieved at least 30% weight loss a level historically associated with bariatric surgery outcomes The 4 mg dose showed a lower rate of discontinuation due to adverse events than even placebo In a study extension to 104 weeks, participants with a starting BMI of 35 or higher who received 12 mg lost up to an average of 85.0 lbs (30.3%)
